Zasocitinib Beats Deucravacitinib on Skin Clearance in Phase 3
Zasocitinib delivered superior skin clearance versus deucravacitinib in a Phase 3 head-to-head plaque psoriasis trial, raising the bar for oral TYK2-directed therapy.
Topic
Deucravacitinib
Topic
Deucravacitinib
Zasocitinib Beats Deucravacitinib in Phase 3 Head-to-Head Psoriasis Trial
Phase 3 head-to-head data show once-daily zasocitinib achieved superior skin clearance versus deucravacitinib in plaque psoriasis…
Zasocitinib Beats Deucravacitinib Head-to-Head in Phase 3 Psoriasis
In the Phase 3 LATITUDE Atlas head-to-head trial, zasocitinib achieved PASI-100 in 36.5% of patients at Week 16 versus 13.9% for…
Takeda reports zasocitinib superior to deucravacitinib
Takeda says its investigational TYK2 inhibitor zasocitinib beat deucravacitinib on efficacy in a head-to-head claim that could re…
Zasocitinib Beats Deucravacitinib in Phase 3 Head-to-Head Trial
Zasocitinib showed superior efficacy versus deucravacitinib in Phase 3 head-to-head psoriasis data, with rapid, durable clearance…
Oral Therapies Position to Reshape Psoriasis and PsA Care
Linda Stein Gold, MD, tells AJMC that emerging oral therapies are set to transform treatment for both psoriasis and psoriatic art…